Developer docs
API playgroundTry for free, no card

Search company profiles

PhotoQ3

Full company profile

uuid002omhw

Namestring
PhotoQ3
Legal namestring
株式会社PhotoQ3
Websiteurl
photoq3.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

PhotoQ3 is a Japanese biotechnology company founded in September 2019 by Takao Hamakubo (University of Tokyo Professor Emeritus) and Yasuhiko Bando, headquartered in Chiyoda-ku, Tokyo with a research facility in Minato-ku, Tokyo. The company develops iTAP (intelligent Targeted Antibody Phototherapy), a platform that integrates photodynamic therapy (PDT) with antibody-toxin conjugates to overcome the endosomal escape bottleneck of conventional immunotoxins. Core technical components include a proprietary recombinant saporin expression system (10–100x higher yield than conventional methods), near-infrared photosensitizing dyes (max absorption 775nm, developed with the University of Tokyo School of Engineering), and flexible N/C-terminal saporin engineering for uniform-DAR immunotoxin production. The company's therapeutic pipeline targets lung cancer, brain tumors, and ovarian cancer, and it holds exclusive implementation rights to PTX3-Fc fusion protein technology (Patent No. 7867700) for infectious disease applications.

The company has two commercial vectors. First, a research-use antibody catalog of monoclonal antibodies (Anti-Robo1, Anti-Cadherin17, Anti-ASNS, Anti-RIG-I, Anti-NFAT, Anti-KLF2, Anti-Ets-1, Anti-DSCR-1) launched in September 2025, sold directly via website inquiry to academic and pharmaceutical researchers in Japan with undisclosed pricing. Second, an iTAP-based therapeutic development business that is pre-revenue and intended to generate future licensing royalties and co-development income from pharmaceutical partners. Supporting revenue streams include joint R&D services and platform access (e.g., collaboration with Tokushu Immuno Research Institute for anti-CD20 immunotoxin development) and an AMED-funded pediatric cancer research project with Kobe University.

PhotoQ3 has raised JPY 200 million via a January 2022 third-party allotment from DEFTA Partners (San Francisco) and completed a FUNDINNO equity crowdfunding campaign in early 2025. The company holds multiple granted patents (Japan No. 7769386, US patent for near-IR dye, Japan No. 7867700) with one new substance patent application filed in August 2025. Operations are Japan-centric, with an employee count of 1–10, scientific advisory support from global PDT authority Harubumi Kato (17th IPA Gold Medal recipient), and collaborations with Nippon Medical School, Kanagawa Dental University, and Tokushu Immuno Research Institute validating the platform across lung, head and neck, and CD20-positive lymphoma indications.

Short descriptiontext

PhotoQ3 is a Japanese biotechnology company that develops iTAP, a light-activated platform combining immunotoxins and photodynamic therapy for cancer treatment, and sells research antibodies developed through that platform to academic and pharmaceutical customers in Japan.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
research antibodies, photodynamic therapy, immunotoxin development, recombinant saporin, cancer therapeutics
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical R&D
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Antibody Product Sales
TypeOne Time License
Description

PhotoQ3 sells a diverse portfolio of high-quality research antibodies developed through its iTAP technology platform. Products launched sequentially starting September 2025. Sales via direct inquiry/contact forms. Targets academic researchers and pharmaceutical companies.

photoq3.com
2Drug Discovery / Therapeutic Development
TypeLicensing Royalties
Description

Core revenue model focused on developing iTAP-based cancer therapeutics. Revenue anticipated from licensing, co-development deals with pharmaceutical companies, and eventual therapeutic product commercialization. Company is in pre-revenue R&D stage.

photoq3.com
3Joint Research & Development Services
TypeProfessional Services
Description

PhotoQ3 provides its saporin manufacturing and immunotoxin engineering platform to partners for co-development. Examples include collaboration with Tokushu Immuno Research Institute for anti-CD20 immunotoxin development.

photoq3.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PhotoQ3 develops the iTAP (intelligent Targeted Antibody Phototherapy) platform, which integrates immunotoxin targeting with photodynamic therapy to dramatically improve endosomal escape and cytosolic delivery of toxin payloads for cancer treatment. The company also manufactures and sells a portfolio of high-quality research-grade monoclonal antibodies developed through its proprietary saporin expression technology, and develops recombinant saporin as a core reagent for immunotoxin engineering.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 10–100x higher saporin expression yield compared to conventional methods
+2 more records
Product overview1 text field

PhotoQ3 operates as a biopharmaceutical company offering a dual portfolio consisting of (1) research-use antibodies developed through their proprietary iTAP technology platform, including 19 distinct monoclonal antibodies targeting proteins such as Robo1, Cadherin17, ASNS, RIG-I, NFAT, KLF2, Ets-1, and DSCR-1, and (2) the iTAP technology platform itself, which combines immunotoxins with photodynamic therapy principles to enhance endosomal escape for cancer treatment applications. The company also manufactures recombinant Saporin, a ribosome-inactivating protein, using proprietary high-efficiency expression technology. Their therapeutic pipeline focuses on lung cancer, malignant brain tumors, and ovarian cancer using the iTAP modality.

Product and service11 records
1iTAP (intelligent Targeted Antibody Phototherapy) Platform
CategoryTherapeutic Technology Platform
Description

Next-generation molecular delivery platform integrating photodynamic therapy into immunotoxins to enhance endosomal escape and enable efficient cytosolic delivery of payloads. Targeted at pharmaceutical partners and academic researchers developing cancer therapeutics for solid tumors (lung, brain, ovarian cancer).

2Recombinant Saporin
CategoryResearch Reagent / Biomanufacturing
Description

A 30-kDa ribosome-inactivating protein (RIP) derived from Saponaria officinalis used as the toxin component in immunotoxin development. Manufactured via proprietary stable recombinant expression technology enabling 10-100x higher expression efficiency than conventional methods. Supplied to pharmaceutical and academic research organizations.

3Anti-Robo1 Antibody
CategoryResearch Antibody
Description

Monoclonal antibodies targeting Robo1, a neuronal axon guidance receptor. Available for academic researchers and pharmaceutical R&D scientists in applications including IHC, WB, IP, and Flow cytometry.

4Anti-Cadherin17 Antibody
CategoryResearch Antibody
Description

Monoclonal antibodies targeting Cadherin-17, a calcium-dependent cell adhesion molecule involved in tumor invasion and metastasis. For oncology research and cancer drug discovery applications.

5Anti-Asparagine Synthetase (ASNS) Antibody
CategoryResearch Antibody
Description

Monoclonal antibodies targeting asparagine synthetase, used for measuring ASNS protein levels in cancer cells and evaluating ASNase sensitivity in cancer therapy. For academic and pharmaceutical oncology research.

6Anti-RIG-I Antibody
CategoryResearch Antibody
Description

Monoclonal antibodies targeting RIG-I (Retinoic Acid-Inducible Gene I), a cytoplasmic pattern recognition receptor for RNA virus detection. For immunology and infectious disease research.

7Anti-NFAT Antibody
CategoryResearch Antibody
Description

Monoclonal antibodies targeting Nuclear Factor of Activated T cells (NFAT) transcription factors. For immunology and cell biology research applications.

8Anti-KLF2 Antibody
CategoryResearch Antibody
Description

Monoclonal antibody targeting KLF2 (Kruppel-like factor 2), a transcription factor essential for T cell survival, migration control, and vascular endothelial cell inflammation suppression. For immunology research.

9Anti-Ets-1 Antibody
CategoryResearch Antibody
Description

Monoclonal antibodies targeting Ets-1 transcription factor, involved in cancer invasion, metastasis, and autoimmune disease inflammation. For oncology and immunology research.

10Anti-DSCR-1 Antibody
CategoryResearch Antibody
Description

Monoclonal antibodies targeting DSCR1 (Down Syndrome Critical Region 1), a negative regulator of calcineurin signaling. For cell signaling and disease research.

11CD20-targeted Novel Immunotoxin (Co-development Program)
CategoryCo-development Therapeutic Program
Description

Co-development immunotoxin therapeutic program for rituximab-resistant malignant lymphoma, combining Tokushu Immuno Research Institute's proprietary anti-CD20 antibody (BM-ca) with PhotoQ3's immunotoxin engineering platform. Targeted at pharmaceutical partners for further development.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Kanagawa Dental University (神奈川歯科大学)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

Joint research demonstrating iTAP efficacy in head and neck cancer using animal models. Results published in the journal Biomedicines (2026). Validates iTAP as a differentiated platform technology for solid tumors.

photoq3.com
2University of Tokyo School of Engineering (東京大学工学系研究科)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-06
Description

Collaborative research with Prof. Akimitsu Okamoto's laboratory to develop novel near-infrared photosensitizing dyes (max absorption 775nm) for iTAP. Resulted in joint publication and US patent grant.

photoq3.com
3Tokushu Immuno Research Institute Co., Ltd. (株式会社特殊免疫研究所)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Joint research agreement to develop a new immunotoxin for rituximab-resistant malignant lymphoma and CD20-positive immune cell diseases. Uses Tokushu's proprietary anti-CD20 antibody (BM-ca) combined with PhotoQ3's immunotoxin engineering platform.

photoq3.com
4Japan Agency for Medical Research and Development (AMED)
Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2025-06-23
Description

PhotoQ3 participates in an AMED drug discovery foundational research project led by Kobe University Graduate School of Medicine. Project focuses on pediatric cancer using FFPE specimen proteomics and next-generation drug discovery, where iTAP technology is applied.

photoq3.com
5Nippon Medical School (日本医科大学)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-24
Description

Collaboration on lung cancer iTAP therapy research, led by Prof. Jitsuo Usuda (Thoracic Surgery). Clinical needs aligned with PhotoQ3's technology development. Resulted in peer-reviewed publication.

photoq3.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech focused on antibody-drug conjugates for hematologic and solid tumors. Closely comparable as a focused ADC developer whose pipeline is built around overcoming delivery and resistance challenges for antibody-targeted payload therapies.

TypeDirect peer
Description

Pioneer of ADC technology (Elahere/DM4 platform), acquired by AbbVie in 2024. Direct peer in antibody-targeted cytotoxic payload chemistry and oncology development.

TypeBroad incumbent
Description

Leading ADC developer (Adcetris, Padcev) now part of Pfizer. A broadly comparable major player in antibody-conjugate oncology whose commercial pipeline dwarfs early-stage entrants in the same category.

TypeDirect peer
Description

Clinical-stage biotech developing next-generation ADC platforms with novel payloads and linkers designed to address delivery and tolerability limitations. Closely comparable as an emerging player seeking differentiation through platform-level chemistry innovation.

TypeBroad incumbent
Description

Global pharma with major ADC franchise (Enhertu co-development with Daiichi Sankyo, Datroway). Comparable as a global ADC acquirer/partner and as the leading commercial force behind antibody-targeted cytotoxic oncology therapy.

TypeDirect peer
Description

Japanese major pharmaceutical company and ADC platform leader behind Enhertu, the most commercially successful ADC to date. Directly comparable as a developer of antibody-conjugate therapeutics with global commercial reach, and the most likely strategic acquirer/partnership counterparty for an iTAP-style platform.

TypeDirect peer
Description

Clinical-stage biotech developing antibody-cytokine fusion products (e.g., L19-TNF, L19-IL2) for oncology. Comparable as a developer of antibody-targeted therapeutics with restricted payloads and academic/spinout DNA similar to PhotoQ3.

TypeEmerging player
Description

Preclinical/early-clinical developer of immunostimulatory antibody conjugates (ISACs) that combine antibody targeting with innate immune activation. Comparable as a smaller-stage platform company working on mechanism-improved conjugates for solid tumors.

TypeEmerging player
Description

Clinical-stage developer of photodynamic therapy (Ruvidar/PBA) for oncology and anti-infective applications. Comparable as a specialist PDT platform player advancing light-activated therapeutics toward commercial and clinical use.

10PeptiDream
TypeRegional player
Description

Japanese biotech specializing in peptide discovery and constrained peptide-based therapeutics for pharma partners. Comparable regional Japanese platform-biotech that monetizes platform technology through licensing to global pharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PhotoQ3

Biopharmaceutical R&Dphotoq3.com

PhotoQ3 is a Japanese biotechnology company that develops iTAP, a light-activated platform combining immunotoxins and photodynamic therapy for cancer treatment, and sells research antibodies developed through that platform to academic and pharmaceutical customers in Japan.

What PhotoQ3 does

PhotoQ3 is a Japanese biotechnology company founded in September 2019 by Takao Hamakubo (University of Tokyo Professor Emeritus) and Yasuhiko Bando, headquartered in Chiyoda-ku, Tokyo with a research facility in Minato-ku, Tokyo. The company develops iTAP (intelligent Targeted Antibody Phototherapy), a platform that integrates photodynamic therapy (PDT) with antibody-toxin conjugates to overcome the endosomal escape bottleneck of conventional immunotoxins. Core technical components include a proprietary recombinant saporin expression system (10–100x higher yield than conventional methods), near-infrared photosensitizing dyes (max absorption 775nm, developed with the University of Tokyo School of Engineering), and flexible N/C-terminal saporin engineering for uniform-DAR immunotoxin production. The company's therapeutic pipeline targets lung cancer, brain tumors, and ovarian cancer, and it holds exclusive implementation rights to PTX3-Fc fusion protein technology (Patent No. 7867700) for infectious disease applications.

The company has two commercial vectors. First, a research-use antibody catalog of monoclonal antibodies (Anti-Robo1, Anti-Cadherin17, Anti-ASNS, Anti-RIG-I, Anti-NFAT, Anti-KLF2, Anti-Ets-1, Anti-DSCR-1) launched in September 2025, sold directly via website inquiry to academic and pharmaceutical researchers in Japan with undisclosed pricing. Second, an iTAP-based therapeutic development business that is pre-revenue and intended to generate future licensing royalties and co-development income from pharmaceutical partners. Supporting revenue streams include joint R&D services and platform access (e.g., collaboration with Tokushu Immuno Research Institute for anti-CD20 immunotoxin development) and an AMED-funded pediatric cancer research project with Kobe University.

PhotoQ3 has raised JPY 200 million via a January 2022 third-party allotment from DEFTA Partners (San Francisco) and completed a FUNDINNO equity crowdfunding campaign in early 2025. The company holds multiple granted patents (Japan No. 7769386, US patent for near-IR dye, Japan No. 7867700) with one new substance patent application filed in August 2025. Operations are Japan-centric, with an employee count of 1–10, scientific advisory support from global PDT authority Harubumi Kato (17th IPA Gold Medal recipient), and collaborations with Nippon Medical School, Kanagawa Dental University, and Tokushu Immuno Research Institute validating the platform across lung, head and neck, and CD20-positive lymphoma indications.

PhotoQ3 firmographics

Firmographics
Name
PhotoQ3
Legal name
株式会社PhotoQ3
Website
https://photoq3.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
PhotoQ3 is a Japanese biotechnology company that develops iTAP, a light-activated platform combining immunotoxins and photodynamic therapy for cancer treatment, and sells research antibodies developed through that platform to academic and pharmaceutical customers in Japan.
Ownership category
akta.pro rank

PhotoQ3 industry classification

Industry
Product category
Biopharmaceutical R&D
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Research antibodies
  • Photodynamic therapy
  • Immunotoxin development
  • Recombinant saporin
  • Cancer therapeutics

Where PhotoQ3 is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

PhotoQ3 business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Antibody Product Sales: PhotoQ3 sells a diverse portfolio of high-quality research antibodies developed through its iTAP technology platform. Products launched sequentially starting September 2025. Sales via direct inquiry/contact forms. Targets academic researchers and pharmaceutical companies.
  2. Drug Discovery / Therapeutic Development: Core revenue model focused on developing iTAP-based cancer therapeutics. Revenue anticipated from licensing, co-development deals with pharmaceutical companies, and eventual therapeutic product commercialization. Company is in pre-revenue R&D stage.
  3. Joint Research & Development Services: PhotoQ3 provides its saporin manufacturing and immunotoxin engineering platform to partners for co-development. Examples include collaboration with Tokushu Immuno Research Institute for anti-CD20 immunotoxin development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

PhotoQ3 product offering

Product offering

Core offering

PhotoQ3 develops the iTAP (intelligent Targeted Antibody Phototherapy) platform, which integrates immunotoxin targeting with photodynamic therapy to dramatically improve endosomal escape and cytosolic delivery of toxin payloads for cancer treatment. The company also manufactures and sells a portfolio of high-quality research-grade monoclonal antibodies developed through its proprietary saporin expression technology, and develops recombinant saporin as a core reagent for immunotoxin engineering.

Product overview

PhotoQ3 operates as a biopharmaceutical company offering a dual portfolio consisting of (1) research-use antibodies developed through their proprietary iTAP technology platform, including 19 distinct monoclonal antibodies targeting proteins such as Robo1, Cadherin17, ASNS, RIG-I, NFAT, KLF2, Ets-1, and DSCR-1, and (2) the iTAP technology platform itself, which combines immunotoxins with photodynamic therapy principles to enhance endosomal escape for cancer treatment applications. The company also manufactures recombinant Saporin, a ribosome-inactivating protein, using proprietary high-efficiency expression technology. Their therapeutic pipeline focuses on lung cancer, malignant brain tumors, and ovarian cancer using the iTAP modality.

Differentiator

Problem solved

Functional benefit

Products and services

  • iTAP (intelligent Targeted Antibody Phototherapy) Platform Next-generation molecular delivery platform integrating photodynamic therapy into immunotoxins to enhance endosomal escape and enable efficient cytosolic delivery of payloads. Targeted at pharmaceutical partners and academic researchers developing cancer therapeutics for solid tumors (lung, brain, ovarian cancer).
  • Recombinant Saporin A 30-kDa ribosome-inactivating protein (RIP) derived from Saponaria officinalis used as the toxin component in immunotoxin development. Manufactured via proprietary stable recombinant expression technology enabling 10-100x higher expression efficiency than conventional methods. Supplied to pharmaceutical and academic research organizations.
  • Anti-Robo1 Antibody Monoclonal antibodies targeting Robo1, a neuronal axon guidance receptor. Available for academic researchers and pharmaceutical R&D scientists in applications including IHC, WB, IP, and Flow cytometry.
  • Anti-Cadherin17 Antibody Monoclonal antibodies targeting Cadherin-17, a calcium-dependent cell adhesion molecule involved in tumor invasion and metastasis. For oncology research and cancer drug discovery applications.
  • Anti-Asparagine Synthetase (ASNS) Antibody Monoclonal antibodies targeting asparagine synthetase, used for measuring ASNS protein levels in cancer cells and evaluating ASNase sensitivity in cancer therapy. For academic and pharmaceutical oncology research.
  • Anti-RIG-I Antibody Monoclonal antibodies targeting RIG-I (Retinoic Acid-Inducible Gene I), a cytoplasmic pattern recognition receptor for RNA virus detection. For immunology and infectious disease research.
  • Anti-NFAT Antibody Monoclonal antibodies targeting Nuclear Factor of Activated T cells (NFAT) transcription factors. For immunology and cell biology research applications.
  • Anti-KLF2 Antibody Monoclonal antibody targeting KLF2 (Kruppel-like factor 2), a transcription factor essential for T cell survival, migration control, and vascular endothelial cell inflammation suppression. For immunology research.
  • Anti-Ets-1 Antibody Monoclonal antibodies targeting Ets-1 transcription factor, involved in cancer invasion, metastasis, and autoimmune disease inflammation. For oncology and immunology research.
  • Anti-DSCR-1 Antibody Monoclonal antibodies targeting DSCR1 (Down Syndrome Critical Region 1), a negative regulator of calcineurin signaling. For cell signaling and disease research.
  • CD20-targeted Novel Immunotoxin (Co-development Program) Co-development immunotoxin therapeutic program for rituximab-resistant malignant lymphoma, combining Tokushu Immuno Research Institute's proprietary anti-CD20 antibody (BM-ca) with PhotoQ3's immunotoxin engineering platform. Targeted at pharmaceutical partners for further development.

Quantifiable outcome

  • 10–100x higher saporin expression yield compared to conventional methods
  • +2 more outcomes

Companies that use PhotoQ3

Customer profile

Segments2 records

Ideal customer profiles2 records

PhotoQ3 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

PhotoQ3 partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and moderate.

  • Kanagawa Dental University (神奈川歯科大学)coreStrategic or Co-development Partner · 3 March 2026Joint research demonstrating iTAP efficacy in head and neck cancer using animal models. Results published in the journal Biomedicines (2026). Validates iTAP as a differentiated platform technology for solid tumors.
  • University of Tokyo School of Engineering (東京大学工学系研究科)coreStrategic or Co-development Partner · 6 December 2025Collaborative research with Prof. Akimitsu Okamoto's laboratory to develop novel near-infrared photosensitizing dyes (max absorption 775nm) for iTAP. Resulted in joint publication and US patent grant.
  • Tokushu Immuno Research Institute Co., Ltd. (株式会社特殊免疫研究所)coreStrategic or Co-development Partner · 1 July 2025Joint research agreement to develop a new immunotoxin for rituximab-resistant malignant lymphoma and CD20-positive immune cell diseases. Uses Tokushu's proprietary anti-CD20 antibody (BM-ca) combined with PhotoQ3's immunotoxin engineering platform.
  • Japan Agency for Medical Research and Development (AMED)moderateStrategic or Co-development Partner · 23 June 2025PhotoQ3 participates in an AMED drug discovery foundational research project led by Kobe University Graduate School of Medicine. Project focuses on pediatric cancer using FFPE specimen proteomics and next-generation drug discovery, where iTAP technology is applied.
  • Nippon Medical School (日本医科大学)coreStrategic or Co-development Partner · 24 January 2023Collaboration on lung cancer iTAP therapy research, led by Prof. Jitsuo Usuda (Thoracic Surgery). Clinical needs aligned with PhotoQ3's technology development. Resulted in peer-reviewed publication.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

PhotoQ3 competitors and assessment

Company assessment

Direct peers

  • ADC Therapeutics: Clinical-stage biotech focused on antibody-drug conjugates for hematologic and solid tumors. Closely comparable as a focused ADC developer whose pipeline is built around overcoming delivery and resistance challenges for antibody-targeted payload therapies.
  • ImmunoGen (AbbVie): Pioneer of ADC technology (Elahere/DM4 platform), acquired by AbbVie in 2024. Direct peer in antibody-targeted cytotoxic payload chemistry and oncology development.
  • Mersana Therapeutics: Clinical-stage biotech developing next-generation ADC platforms with novel payloads and linkers designed to address delivery and tolerability limitations. Closely comparable as an emerging player seeking differentiation through platform-level chemistry innovation.
  • Daiichi Sankyo: Japanese major pharmaceutical company and ADC platform leader behind Enhertu, the most commercially successful ADC to date. Directly comparable as a developer of antibody-conjugate therapeutics with global commercial reach, and the most likely strategic acquirer/partnership counterparty for an iTAP-style platform.
  • Philogen: Clinical-stage biotech developing antibody-cytokine fusion products (e.g., L19-TNF, L19-IL2) for oncology. Comparable as a developer of antibody-targeted therapeutics with restricted payloads and academic/spinout DNA similar to PhotoQ3.

Broad incumbents

  • Seagen (Pfizer): Leading ADC developer (Adcetris, Padcev) now part of Pfizer. A broadly comparable major player in antibody-conjugate oncology whose commercial pipeline dwarfs early-stage entrants in the same category.
  • AstraZeneca: Global pharma with major ADC franchise (Enhertu co-development with Daiichi Sankyo, Datroway). Comparable as a global ADC acquirer/partner and as the leading commercial force behind antibody-targeted cytotoxic oncology therapy.

Emerging players

  • Bolt Biotherapeutics: Preclinical/early-clinical developer of immunostimulatory antibody conjugates (ISACs) that combine antibody targeting with innate immune activation. Comparable as a smaller-stage platform company working on mechanism-improved conjugates for solid tumors.
  • Theralase Technologies: Clinical-stage developer of photodynamic therapy (Ruvidar/PBA) for oncology and anti-infective applications. Comparable as a specialist PDT platform player advancing light-activated therapeutics toward commercial and clinical use.

Regional players

  • PeptiDream: Japanese biotech specializing in peptide discovery and constrained peptide-based therapeutics for pharma partners. Comparable regional Japanese platform-biotech that monetizes platform technology through licensing to global pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

PhotoQ3 social profiles

Digital presence

PhotoQ3 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PhotoQ3 leadership team

Management profile

Number of profiles

Profiles6 records

PhotoQ3 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PhotoQ3 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PhotoQ3

What does PhotoQ3 do?

PhotoQ3 develops the iTAP (intelligent Targeted Antibody Phototherapy) platform, which integrates immunotoxin targeting with photodynamic therapy to dramatically improve endosomal escape and cytosolic delivery of toxin payloads for cancer treatment. The company also manufactures and sells a portfolio of high-quality research-grade monoclonal antibodies developed through its proprietary saporin expression technology, and develops recombinant saporin as a core reagent for immunotoxin engineering.

Is PhotoQ3 a public or private company?

PhotoQ3 is a private company. It is classified as venture growth investor backed and is currently operating.

When was PhotoQ3 founded?

PhotoQ3 was founded in 2019. It employs 1 to 10 people.

Where is PhotoQ3 based?

PhotoQ3 is headquartered in Tokyo, Japan, in the Asia region.

How does PhotoQ3 make money?

Three revenue lines are on record. Antibody Product Sales are the primary driver. The others are drug Discovery / Therapeutic Development and joint Research & Development Services.

Who are PhotoQ3's main competitors?

Direct peers on record are ADC Therapeutics, ImmunoGen (AbbVie), Mersana Therapeutics, Daiichi Sankyo and Philogen. Broad incumbents are Seagen (Pfizer) and AstraZeneca. Emerging players are Bolt Biotherapeutics and Theralase Technologies. PeptiDream is listed as a regional player.

Does PhotoQ3 have an API?

No public API is recorded for PhotoQ3.

What industry is PhotoQ3 in?

PhotoQ3's product category is Biopharmaceutical R&D. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325413 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales